Vector Science and Therapeutics Corp. is a Canada-based company. The Company develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions. The Company's product platforms and applications include Laparoscopic Atomizing Solution System (LASS) and Biomechanical Transdermal Device (BTP). The LASS Platform is an atomizing solution system designed to deliver therapeutics/anesthetics in a manner that infiltrates tissue to have a specific therapeutic effect. VectorMist is a catheter-based system designed for targeted delivery of atomized therapeutics directly into the surgical field during laparoscopic procedures. Vector BTP is an electrical biomechanical platform that functions as both a standalone therapeutic intervention and a drug delivery platform competing directly with sustained acoustic medicine devices and pulsed electromagnetic field devices in the regenerative and sports medicine segments.

Employees

Sector

Investment Holding Companies

More about the company

Quotes

Date	Price	Change	Volume
27/08/26	CA$2.010	-4.74%	40,723
26/08/26	CA$2.110	+10.47%	629,741
25/08/26	CA$1.910	+6.11%	180,625
24/08/26	CA$1.800	-1.64%	207,606
21/08/26	CA$1.830	+2.81%	128,748

Delayed Quote Toronto S.E.

More quotes

Delayed Toronto S.E. 15:08:53 27/08/2026 BST			5-day change	1st Jan Change
2.010 ^CAD	-4.74%		+12.92%	+3,920.00%

08-24	Vector Science Starts Manufacturing Pharma-Grade Peptides	MT
08-24	Vector Science & Therapeutics Increases Peptide Manufacturing Capacity At Lyogenesis Facility	CI

Market Cap	238M 204M 191M 175M 330M 22.66B 332M 2.27B 878M 11.43B 892M 873M 37.87B	P/E 2024 *	-	P/E 2025	-0.29x
Enterprise Value	235M 201M 189M 173M 326M 22.39B 327M 2.24B 867M 11.29B 881M 862M 37.41B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	79.62%	Yield 2024 *	-	Yield 2025	-

08-24	Vector Science Starts Manufacturing Pharma-Grade Peptides	MT
08-24	Vector Science & Therapeutics Increases Peptide Manufacturing Capacity At Lyogenesis Facility	CI
08-20	Vector Science and Therapeutics Corp Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	CI
08-17	Vector Science and Therapeutics Signs Amended 10-Year Manufacturing and Testing Agreement	MT
08-17	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement With LyoGenesis Holdings LLC	CI
07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-24	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
07-21	Vector Science to Build Distributor Network For Peptide Portfolio Commercialization	MT
07-17	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist	CI
07-17	Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax	MT
07-15	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery	CI
07-08	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board	CI
07-07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus	CI

08-26	Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options	AQ
08-24	Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online	AQ
08-20	Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	AQ
08-19	/C O R R E C T I O N -- Vector Sciences & Therapeutics/	AQ
08-17	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings	AQ

Vector Science and Therapeutics Corp. Share Price

Stocks

PAIN

CA92244M1041

Investment Holding Companies

Valuation : Vector Science and Therapeutics Corp.

Chart: Vector Science and Therapeutics Corp.

Latest news : Vector Science and Therapeutics Corp.

Press Releases : Vector Science and Therapeutics Corp.

Quotes and Performance

Price Extremes

Latest insider transactions

Shell Companies

Financials

Company Profile

Quotes

1 day	-4.74%
1 week	+12.92%
Current month	+24.84%
1 month	+20.36%
3 months	+54.62%
6 months	+443.24%
Current year	+3,920.00%

1 week	1.68	2.24
1 month	1.5	2.24
Current year	0.35	2.65
1 year	0.35	2.65
3 years	0.03	2.65
5 years	0.03	2.65
10 years	0.03	2.65

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VECTOR SCIENCE AND THERAPEUTICS CORP.	-4.74%	+12.92%	+443.24%	+3,250.00%	238M
CHURCHILL CAPITAL CORP XI	-1.99%	+5.12%	-	-	825M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.05%	-0.15%	-	-	645M
CENTIEL AG	-2.41%	-12.03%	+263.31%	-76.56%	630M
CHURCHILL CAPITAL CORP XII	+0.74%	+1.03%	-	-	601M
BAIN CAPITAL GSS INVESTMENT CORP.	0.00%	-0.39%	-	-	600M
CANTOR EQUITY PARTNERS IV, INC.	+0.48%	+0.48%	+2.96%	-	594M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.17%	-1.12%	-	-	567M
CHURCHILL CAPITAL CORP XIII	0.00%	+0.38%	-	-	509M
Average	-0.93%	+0.30%	+236.51%	+1,586.72%	578.77M
Weighted average by Cap.	-0.74%	-0.04%	+186.78%	+834.40%

	*	1 *
Net sales	-	-
Net income	-	-
Net Debt	-	-